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Introduction 
Ischemia-reperfusion (IR) injury is a known 
complication of cardiopulmonary bypass (CPB) 
and cardiac surgery [1]. IR injury is defined as the 
myocardial damage that occurs because of the 
restoration of blood flow after a period of 
coronary occlusion [2]. IR injury to multiple organs 
may also occur in association with a systemic 
inflammatory response syndrome (SIRS), which is 
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Abstract 
Background: Myocardial injury during cardiac surgery is associated with increased 
morbidity and mortality, and proper myocardial protection improves surgical 
outcomes. We aimed to study the role of preoperative nicorandil in myocardial 
protection during valve replacement surgery.  
Methods: The study included 40 patients who were randomized into two groups: 
control group, and nicorandil group. Preoperative, intraoperative, and 
postoperative data were collected. Creatine kinase- MB (CK-MB), troponin I, 
malondialdehyde (MDA), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-
α) were measured 24-hours before surgery then 4, 12 and 48 hours after aortic 
cross-clamp removal. 
Results: Nicorandil significantly decreased MDA (p=0.005 and 0.036), TNF-α (p< 
0.001), IL-6 (p<0.001 and 0.003) 4 and 12 hours following the removal of aortic 
clamp compared to the control group. Additionally, It significantly reduced CK-MB 
(p< 0.0001 and 0.0002) and troponin-I (p= 0.0002 and < 0.0001) 4 and 12 hours 
after the removal of the aortic clamp, respectively. However, there was no 
significant difference in MDA, TNF-α, IL-6, CK-MB, and troponin-I levels between 
the nicorandil and the control group after 48 hours following the removal of aortic 
clamping (p= 0.084; 0.64; 0.12; 0.12; 0.75; respectively).  
Conclusions: Nicorandil reduced myocardial injury significantly in valve 
replacement surgery. Nicorandil decreased CK-MB and troponin I and improved 
postoperative left ventricular ejection fraction. 
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responsible for the increased morbidity and 
mortality after open heart surgery [3].  
The elevated levels of the circulating free 
radicals that occur during IR injury result in 
metabolic, functional, and structural alterations 
[1]. Moreover, IR injury and CPB can trigger an 
inflammatory response, which may have a role in 
increasing postoperative complications [4]. 
Several biomarkers were evaluated clinically to 
measure the degree of myocardial injury after 
cardiac surgery, and the most commonly used 
markers are creatine kinase-MB and troponin I [5]. 
Nicorandil, a drug used in the management of 
angina, has a potassium channel (K-ATP) opening 
action, in addition to its nitrate like action [6]. The 
effect of this drug on the outcomes after valve 
surgery has not been evaluated. The objective of 
our study is to evaluate the effect of the 
potassium channel opener (nicorandil) on the 
oxidative stress, proinflammatory cytokines during 
myocardial ischemia/reperfusion injury and its 
impact on the outcomes after heart valve surgery. 
Patients and Methods: 
Design and Patients:  
The study is a prospective randomized 
controlled trial and was carried out on 40 patients 
who underwent valve replacement surgery in the 
Cardiothoracic Surgery Department, Tanta 
University. The study was approved by the 
Research Ethics Committee, Faculty of Medicine, 
and was performed from January 2018 till June 
2018. We excluded patients with a concomitant 
surgical procedure (ischemic heart disease or 
congenital anomalies) or those with severe 
systemic (endocrine, hepatic, renal, and 
pulmonary) disorders (Figure 1). 
The patients were randomized by block 
randomization into two groups: control group (20 
patients) and nicorandil group (20 patients); the 
last group received nicorandil for a period ranged 
from 5 to 15 days; starting from the first day of 
preparation for surgery and ending in the night 
before surgery. The dose of nicorandil was 20 mg 
daily divided into two doses.  
Surgical technique: 
Surgery was carried out to both groups using 
the same techniques. Cardiopulmonary bypass 
with moderate hypothermia (28°C to 32°C) was 
applied, and antegrade or retrograde cold 
crystalloid cardioplegia was used for myocardial 
protection. The average arterial blood pressure 
was maintained between 50 and 70 mmHg, 
mechanical prostheses were used in all patients, 
and total bypass time and ischemic time were 
recorded.
Figure 1: Study flowchart
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Table 1: Pre- and intraoperative data (Continuous variables are presented as mean± standard deviation and categorical 
variables as number and percent) 
Control group Nicorandil group p. value
Age (years) 40.8±12.19 37.9±11.81 0.449 
Sex 
Male 8(40%) 9(45%) 
0.749 
Female 12(60%) 11(55%) 
Diabetes mellitus 2(10%) 3(15%) 0.633 
Hypertension 3(15%) 4(20%) 0.677 
Preoperative LVEF (%) 65.85±5.25 64.5±4.62 0.393 
preoperative CK-MB (ng/L) 5.65±0.55 5.56±0.66 0.652 
Preoperative Troponin I (ng/L) 0.209±0.07 0.213±0.07 0.855 
Type of valve surgery 
DVR 3(15%) 4(20%) 
0.913 
AVR 3(15%) 3(15%) 
MVR+TR 2(10%) 3(15%) 
MVR 12(60%) 10(50%) 
Total bypass time (Minutes) 73.7±13.04 80.15±12.67 0.121 
Ischemic time (Minutes) 54.75±11.18 57.9±10.52 0.365 
AVR: aortic valve replacement; CK-MB; Creatine kinase- MB; DVR: double valve replacement; LVEF%: left 
ventricular ejection fraction; MVR: mitral valve replacement; TR: tricuspid replacement 
Study outcomes: 
Left ventricular ejection fraction (LVEF %) was 
assessed before and after surgery by 
echocardiography. Venous blood samples for 
creatine kinase- MB (CK-MB), troponin I, 
malondialdehyde (MDA), interleukin-6 (IL-6) and 
tumor necrosis factor-alpha (TNF-α) were 
measured 24 hours before surgery then 4, 12 and 
48 hours after aortic cross-clamp removal. 
Measurements of malondialdehyde: 
Serum malondialdehyde (MDA) was measured 
using the Draper and Hadly method [7]. The pink 
color is formed because of the reaction between 
MDA and thiobarbituric acid in an acidic medium 
at high temperature and then extracted and 
measured at 535 nm. 
Measurement of CK-MB: 
Serum isoenzyme of CKMB concentration was 
determined by a kinetic method utilizing a 
commercially available assay (Spectrum 
diagnostics, Hannover, Germany). The mean 
reading of serial readings every 1 minute for 4 
readings at 340 nm was considered.  
Measurement of TNF- α, Il-6, and troponin-I: 
The serum concentration of TNF- α, Il-6 and 
troponin-I were determined using enzyme-linked 
immunosorbent assay (ELISA) kits (Orgenium 
Laboratories, Vantaa, Finland; Ray Biotech Inc., 
Norcross, USA and Monobind Inc., Lake Forest, 
USA respectively).  
Statistical analysis: 
We analyzed data using SPSS version 18 (IBM 
Corp- Chicago- IL- USA) and presented the 
continuous variables as mean ± standard deviation 
(SD). Concerning qualitative data, Chi-square test 
(X2) was used to compare the two groups, and 
data were presented as number and percentage. 
Student’s t-test or Man-Whitney test was used to 
compare quantitative data between the two 
groups. A p-value was considered statistically 
significant if it was less than 0.05. 
Results 
There was no statistically significant difference 
between the two groups regarding the pre- and 
intraoperative data (Table 1). 
CK-MB and troponin I levels at 4, 12, and 48 
hours after removal of aortic cross-clamp were 
significantly lower in the nicorandil group. CK-MB 
levels increased postoperatively in both groups 
and showed a peak value at 4 hours after removal 
of aortic clamping then it decreased gradually. 
However, CK-MB levels at 4 hours and 12 hours 
after cross-clamp removal were significantly lower 
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Figure 2: Creatine kinase- MB (CK-MB) change in both 
groups 
in nicorandil group, and there was no significant 
difference in CK-MB levels in both groups after 48 
hours following the removal of aortic clamp 
(Figure 2). Troponin I levels increased after 
surgery in both groups and peaked at 12 hours 
after removal of the aortic clamp then decreased 
gradually. Troponin I levels 4 hours and 12 hours 
after removal of cross-clamp were significantly 
lower in the nicorandil group compared to their 
respective values in the control group, and there 
was no significant difference in troponin I level in 
both groups after 48 hours following the removal 
of aortic clamp (Figure 3). 
Figure 3: Troponin I change in both groups 
The preoperative LVEF of both groups were 
not significantly different, while postoperative 
LVEF was higher in the nicorandil group compared 
to the control group, as shown in Figure 4. 
The baseline values of the mean levels of MDA, 
IL-6, and TNF-α were not significantly different in 
both groups (Table 2). After aortic unclamping, 
the mean levels of MDA and TNF-α and IL-6 were 
elevated in both groups. MDA concentrations 
increased after surgery in both groups showing a 
peak value at 4 hours then decreased gradually. 
MDA levels at 4 hours and 12 hours after de-
clamping the aorta were significantly lower in the 
nicorandil group. There was no significant 
difference in MDA levels after 48 hours of aortic 
de-clamping in both groups. TNF-α and IL-6 
increased after surgery and peaked at 4 hours 
after aortic unclamping then the levels of both 
TNF-α and IL-6 decreased gradually in both 
groups. However, TNF-α and IL-6 concentrations 
at 4 hours and 12 hours after cross unclamping 
were significantly lower in nicorandil group 
compared to their respective values in control 
group, and there was no significant difference in 
TNF-α and IL-6 levels in both groups after 48 
hours from aortic unclamping (Table 2). 
Figure 4: Preoperative and postoperative left 
ventricular ejection fraction (LVEF%) levels in both 
groups. (Values are shown as mean ± standard 
deviation 
Discussion 
Ischemia-reperfusion (IR) injury after open 
heart surgery is usually associated with increased 
complications and mortality; therefore, adequate 
myocardial protection is critical to prevent 
myocardial injury after CPB [8]. In the present 
study, nicorandil showed a significant 
improvement in postoperative LVEF compared to 
the control group which indicates a myocardial 
protecting effect of nicorandil after valvular 
cardiac surgery, and this was proved laboratory by 
detecting the decrease in the postoperative CK-
MB and troponin I levels compared to the control 
group. These findings are in agreement with other
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Table 2: Effect of nicorandil on malondialdehyde (MDA), tumor necrosis factor- α (TNF-α), interleukin-6 (IL-6) measured 
in ng/L 
Control Nicorandil p. value
Preoperative MDA 4.05±0.49 4.09±0.52 0.825 
MDA (4hours) 5.74±0.66 5.13±0.63 0.005 
MDA (12 hours) 5.21±0.68 4.76±0.62 0.036 
MDA (48 hours) 4.42±0.54 4.38±0.55 0.836 
Preoperative TNF-α 11.38±1.17 12.04±1.3 0.101 
TNF-α (4 hours) 19.4±2.42 15.08±1.43 ˂0.001 
TNF-α (12 hours) 15.37±2.26 13.07±1.48 ˂0.001 
TNF-α (48 hours) 12.29±1.26 12.1±1.25 0.638 
Preoperative IL-6 18.42±1.41 19.08±1.55 0.165 
IL-6 (4 hours) 35.61±2.89 28.06±3.4 ˂0.001 
IL-6 (12 hours) 28.84±5.47 24.17±3.36 0.003 
IL-6 (48 hours) 22.62±1.54 21.65±2.25 0.122 
MDA: malondialdehyde, TNF-α: tumor necrosis factor alpha, IL-6: interleukin 6 
studies that showed that nicorandil provided 
myocardial protection in different situations, 
such as during coronary angioplasty [9, 10]. 
Oxidative stress that arises from the 
overproduction of oxygen free radicals during the 
reperfusion of ischemic myocardium is the leading 
cause of IR injury [11].  The burst of reactive 
oxygen species (ROS) starts in the first minutes 
after reperfusion. ROS are generated from many 
sources; leakage of the mitochondrial electron, 
lipoxygenase, xanthine oxidase, and NADPH-
oxidases [12-14]. ROS result in many detrimental 
processes as peroxidation of lipid membranes, 
macromolecule oxidation, membrane 
dysfunction, altered calcium homeostasis, DNA 
lesions, the attraction of neutrophils, apoptosis 
which is triggered by the opening of the 
permeability transition pores in mitochondria 
which all result in myocardial damage [13-15]. 
Direct measurement of oxygen free radicals 
that proves the presence of oxidative stress is 
difficult in humans because of their transient 
nature and difficulty of the measurement 
techniques. That’s why an indirect marker of 
oxidative stress such as MDA is used in the present 
study to reflect the extent of oxidative stress. MDA 
is a known product of polyunsaturated fatty acid 
peroxidation, and oxidative stress leads to 
depletion of antioxidant capacity of plasma 
resulting in higher lipid peroxidation and increases 
the production MDA [16].  
In the present study, the serum MDA 
concentration increased after valvular surgery, 
but this increase in MDA levels after 4 and 12 h 
was lower significantly in the nicorandil group in 
comparison to the control group. This may be 
explained by the ability of nicorandil to reduce the 
mitochondrial formation of ROS by opening the 
mitochondrial ATP-sensitive K channel, that 
evokes a mitochondrial depolarization and 
suppresses ROS formation [17]. In addition; 
nicorandil is thought to have free radical 
scavenging action [18]. 
There is a close relation between ROS 
production and IR injury and systemic 
inflammatory response during cardiopulmonary 
bypass [19]. In cardiac surgery; the mechanisms 
causing oxidative stress and SIR are similar; 
including the exposure of blood to tubes used in 
CPB, the surgical trauma itself, and sudden 
excessive changes in body temperature [20]. 
The systemic inflammatory response involves 
leakage of cytokines, such as IL-6 and TNF-α, which 
play an important role in myocardial IR injury and 
cause damage to the myocardium [19]. 
Reperfusion of the ischemic tissue leads to higher 
chemotactic factors concentrations that attract 
macrophages, monocytes, and 
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polymorphonuclear leucocytes (PNL) and that 
initiate an inflammatory response and tissue 
damage [21]. Migration of PNLs leads to increased 
endothelial damage and increase the secretion of 
IL-6 and TNF-α. Excessive inflammatory cytokine 
production activates further neutrophils and 
exacerbates tissue damage [22]. 
Our study showed high levels of serum TNF-α 
and IL-6 after valvular surgery. However, this 
increase in TNF-α and IL-6 levels after 4 and 12 h 
was lower in the nicorandil group compared to the 
control group. Nicorandil is reported to modulate 
the inflammatory mediators’ release and inhibit 
the release TNF-α from a lymphocyte by Wei and 
associates [23] which is in agreement with our 
results. 
The ability of nicorandil to decrease the 
proinflammatory cytokines may be related to 
nitric oxide that is liberated from nicorandil and 
may be involved in suppression of nuclear factor-
κB which regulates the expression of many genes 
including pro-inflammatory cytokines  (TNF-α and 
IL-6) and therefore decreasing the level of these 
proinflammatory cytokines by blocking their 
mRNA expression [24,25]. 
Limitations: 
There are several limitations of the study, 
including the inability to study the effect of 
different durations and routes of administration of 
nicorandil on myocardial protection, which can be 
assessed in further studies. The preoperative 
duration of nicorandil varied from 5-15 days, and 
the optimal period was not evaluated. 
Additionally, the study did not evaluate whether 
the effect of nicorandil is related to a specific dose 
since all patients had the same daily dose. Another 
issue is masking the treatment since we did not 
use a placebo. However, the endpoints used were 
objective and included laboratory measurements, 
and the person who performed the analyses was 
blinded to patients’ assignment. 
Conclusion 
Our study suggests that nicorandil reduces the 
ischemia and reperfusion injury presented in an 
improvement of postoperative LVEF and the 
decrease in CK-MB and troponin I enzymes. 
Nicorandil may exert this effect through its ability 
to suppress oxygen free radicals and 
proinflammatory cytokine production such as 
TNF-α and IL-6.  Nicorandil may be a promising 
agent for cardioprotection during heart valve 
surgery. 
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